Project Grant R43AI100753

Federal Project Grant Award Summary Mucommune LLC received a $310,136 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 21, 2025, with a completion date of July 31, 2027. The grant funds development of a lactic acid (LA)-releasing intravaginal ring (IVR) designed to treat and prevent bacterial vaginosis (BV), a prevalent vaginal infection affecting millions of women in...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...

Federal Grant Award Summary Mucommune LLC received a $1,025,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 23, 2025, with a completion date of May 31, 2028. The award supports the development of MM-009, a lactic acid-releasing intravaginal ring (LA-IVR) designed to treat and prevent bacterial vaginosis (BV). The product is engineered to deliver lactic acid over a...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, Davis. This funding will support a collaborative HIV vaccine research program, referred to as OPTI-FLIP, that aims to develop a vaccine regimen leveraging cooperative interactions between antibody and T-cell immune responses. The key research activities funded under this grant...

This $273,424 federal Project Grant was awarded on April 9, 2025 by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports research to determine if HIV-1 exposed infants passively immunized with CD4-binding site broadly neutralizing antibodies (bnAbs) in the IMPAACT P1112 clinical trial achieved high serum neutralization titers, which is a key biomarker...

Federal Grant Award Summary Siolta Therapeutics Inc. received a Project Grant of $529,498 from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on August 5, 2025, with a completion date of July 31, 2028. The company is developing STMC-105, a multispecies live biotherapeutic product (LBP) designed to prevent recurrent bacterial vaginosis (RBV) in women of reproductive age. The therapeutic product combines...

Federal Project Grant Award Summary Weill Medical College of Cornell University received a $4.63M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion scheduled for June 30, 2030. The project, titled "Translating Germline-Targeting HIV Env SOSIP Immunization of Infants," focuses on developing and optimizing a pediatric HIV vaccine regimen...

Federal Project Grant Award Summary Weill Medical College of Cornell University received a $4.69M Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 25, 2025, with completion targeted for August 31, 2029. The project, conducted in New York, focuses on leveraging novel pediatric simian-human immunodeficiency viruses (SHIVs) to identify and validate biomarkers predictive of broadly...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...